1. Liao, Zhangyuan, She, Chunhua, Ma, Li, Wang, Peng, Li, Wenliang. 2019. KDELR2 Promotes Glioblastoma Tumorigenesis Targeted by HIF1a via mTOR Signaling Pathway. In Cellular and molecular neurobiology, 39, 1207-1215. doi:10.1007/s10571-019-00715-2. https://pubmed.ncbi.nlm.nih.gov/31342232/
2. Jovanovic, Milena, Marini, Joan C. 2024. Update on the Genetics of Osteogenesis Imperfecta. In Calcified tissue international, 115, 891-914. doi:10.1007/s00223-024-01266-5. https://pubmed.ncbi.nlm.nih.gov/39127989/
3. Wei, Haoran, Ma, Wenhao, Lu, Xiaofei, Gao, Ping, Zhong, Xiuying. 2021. KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression. In Cancer communications (London, England), 41, 904-920. doi:10.1002/cac2.12180. https://pubmed.ncbi.nlm.nih.gov/34146461/
4. Mao, Hui, Nian, Jiang, Wang, Zhao, Li, XueJun, Huang, ChunHai. 2020. KDELR2 is an unfavorable prognostic biomarker and regulates CCND1 to promote tumor progression in glioma. In Pathology, research and practice, 216, 152996. doi:10.1016/j.prp.2020.152996. https://pubmed.ncbi.nlm.nih.gov/32534703/
5. Tiwarekar, Vishakha, Fehrholz, Markus, Schneider-Schaulies, Jürgen. 2019. KDELR2 Competes with Measles Virus Envelope Proteins for Cellular Chaperones Reducing Their Chaperone-Mediated Cell Surface Transport. In Viruses, 11, . doi:10.3390/v11010027. https://pubmed.ncbi.nlm.nih.gov/30621148/
智鼠故事 
